Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nicholas T. Gutsche"'
Autor:
Meghan M. Bell, Nicholas T. Gutsche, A. Paden King, Kwamena E. Baidoo, Olivia J. Kelada, Peter L. Choyke, Freddy E. Escorcia
Publikováno v:
Molecules, Vol 26, Iss 1, p 4 (2020)
Glypican-3 (GPC3) is expressed in 75% of hepatocellular carcinoma (HCC), but not normal liver, making it a promising HCC therapeutic target. GC33 is a full-length humanized monoclonal IgG1 specific to GPC3 that can localize to HCC in vivo. GC33 alone
Externí odkaz:
https://doaj.org/article/e91f797894a9415aa0f6dfa7ebbad6a1
Autor:
Stanley Fayn, A. Paden King, Nicholas T. Gutsche, Zhijian Duan, Jesse Buffington, Colleen P. Olkowski, Ying Fu, Jessica Hong, Deepak Sail, Kwamena E. Baidoo, Rolf E. Swenson, Ross W. Cheloha, Mitchell Ho, Peter Choyke, Freddy Escorcia
Publikováno v:
Journal of Nuclear Medicine. :jnumed.122.265171
Autor:
Patrícia M. R. Pereira, Jacob L. Houghton, Nicholas T. Gutsche, Freddy E. Escorcia, Andrew Cho, Jason S. Lewis, Kwamena E. Baidoo, Dalya Abdel-Atti
Publikováno v:
Theranostics
Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in p
Autor:
Raju Natarajan, Ying Fu, Olivia J. Kelada, Freddy E. Escorcia, Peter L. Choyke, Nicholas T. Gutsche, Rose M. Berman, Jessica Hong, Mitchell Ho, Rolf E. Swenson
Publikováno v:
Cancer Biotherapy & Radiopharmaceuticals
Background: Glypican 3 (GPC3), a plasma membrane heparan sulfate proteoglycan, is overexpressed on human hepatocellular carcinoma and may represent a promising biomarker. Several studies have reported peptides that selectively bind to GPC3 and could
Autor:
Alexandria Villmer, Nicholas T. Gutsche, Daniel L.J. Thorek, Diane Abou, Joshua J. Woods, Hanwen Zhang, Kwamena E. Baidoo, Freddy E. Escorcia, Justin J. Wilson, Nikki A. Thiele
Publikováno v:
Chemical Science
Targeted alpha therapy is an emerging strategy for the treatment of disseminated cancer. [223Ra]RaCl2 is the only clinically approved alpha particle-emitting drug, and it is used to treat castrate-resistant prostate cancer bone metastases, to which [
Autor:
Nicholas T. Gutsche, Kwamena E. Baidoo, A Paden King, Meghan Bell, Olivia J. Kelada, Freddy E. Escorcia, Peter L. Choyke
Publikováno v:
Molecules
Molecules, Vol 26, Iss 4, p 4 (2021)
Volume 26
Issue 1
Molecules, Vol 26, Iss 4, p 4 (2021)
Volume 26
Issue 1
Glypican-3 (GPC3) is expressed in 75% of hepatocellular carcinoma (HCC), but not normal liver, making it a promising HCC therapeutic target. GC33 is a full-length humanized monoclonal IgG1 specific to GPC3 that can localize to HCC in vivo. GC33 alone
Autor:
Nicholas T. Gutsche, Meghan Bell, Olivia J. Kelada, Blake M. Warner, Freddy E. Escorcia, Jessica Hong, Kwamena E. Baidoo, Mitchell Ho, Peter L. Choyke, Rose M. Berman, Lawrence P. Szajek
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:S180-S181
BackgroundHepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. While conventional imaging approaches like ultrasound, CT, and MRI play critical roles in the diagnosis and surveillance of HCC, improved methods for detection and as